Loading
Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.
Alexander Perl was principal investigator of ADMIRAL, which showed the FLT3 inhibitor gilteritinib doubles survival versus salvage chemotherapy in relapsed or refractory FLT3-mutant AML, the first randomised trial to establish single-agent targeted therapy in the disease. He led the earlier phase 1/2 gilteritinib study and studies of resistance to FLT3 inhibition. He leads AML clinical research at Penn.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tags aml, flt3.
Shares FLT3, Acute myeloid leukaemia and the tag aml.
Shares Acute myeloid leukaemia and the tags aml, targeted-therapy.
Shares FLT3, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares FLT3, Acute myeloid leukaemia and the tag flt3.
Shares FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia and the tag flt3.
Shares Small-molecule kinase inhibitors and the tag targeted-therapy.